KALA BIO, INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
KALA BIO, INC. (KALA) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $160.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-04-15.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-04-15
- KALA BIO, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-12-31 was $0.00.
- KALA BIO, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-12-31 was $0.00.
- KALA BIO, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-09-30 was $0.00.
- KALA BIO, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-06-30 was $0.00.
- KALA BIO, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $160.00K, a 92.66% decline from fiscal 2023.
- KALA BIO, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $2.18M, a 414.15% increase from fiscal 2022.
- KALA BIO, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $424.00K, a 64.96% decline from fiscal 2021.
- KALA BIO, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $1.21M.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2024-12-31 | $160.00K 10-K · filed 2026-04-15 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $2.18M 10-K · filed 2025-03-31 | ||
| 2023-09-30 | $2.18M 10-Q · filed 2024-11-12 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $0.00 derived: sum of 2 quarters · filed 2024-03-29 | $0.00 derived: sum of 3 quarters · filed 2024-03-29 | $424.00K 10-K · filed 2024-03-29 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $0.00 derived: sum of 2 quarters · filed 2023-11-13 | $424.00K 10-Q · filed 2023-11-13 | $423.00K derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $424.00K 10-Q · filed 2023-08-04 | $423.00K derived: sum of 3 quarters · filed 2023-08-04 | $416.00K derived: sum of 4 quarters · filed 2023-08-04 |
| 2022-03-31 | $424.00K 10-Q · filed 2023-05-09 | $423.00K derived: sum of 2 quarters · filed 2023-05-09 | $416.00K derived: sum of 3 quarters · filed 2023-05-09 | $416.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | -$8.00K derived: sum of 2 quarters · filed 2023-03-03 | -$8.00K derived: sum of 3 quarters · filed 2023-03-03 | $1.21M 10-K · filed 2023-03-03 |
| 2021-09-30 | -$7.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$7.00K derived: sum of 2 quarters · filed 2022-11-08 | $1.21M 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $1.22M 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $1.22M 10-Q · filed 2022-05-16 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $0.00 derived: sum of 2 quarters · filed 2021-02-25 | -$26.00K derived: sum of 3 quarters · filed 2021-02-25 | $1.85M 10-K · filed 2021-02-25 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$26.00K derived: sum of 2 quarters · filed 2020-11-05 | $1.85M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | -$26.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $1.85M 10-Q · filed 2020-08-06 | ||
| 2019-03-31 | $1.88M 10-Q · filed 2020-05-07 | |||
| 2018-12-31 | $29.43M 10-K · filed 2020-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |